Novavax (NVAX) has skyrocketed 211.2% in the year-to-date period against the industry’s 3.1% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average.NVAX Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis surge in share price can be attributed to Novavax’s recently signed multi-billion dollar deal with pharma giant Sanofi (SNY) to market its protein-based COVID ...